In DLBCL, CD68+CD163+ M2 macrophages are associated with poor clinical outcome (Komohara et al., 2015; Guo et al., 2016) and more frequent extra-nodal involvement (Li Y.-L. The gene discussed is CD163; the disease is diffuse large B-cell lymphoma.